FDA Approves Medafor's Unique Hemostatic Technology
Regulatory Clearance Received for Professional and Over-the-Counter Topical Markets

Minneapolis, Minn., December 2001 - Medafor, Inc., announced today that the company has received regulatory clearance from the Food and Drug Administration (FDA) to market its breakthrough technology as a topical hemostat for the local management of bleeding wounds. TraumaDEX has been cleared for use by doctors and medical services personnel for temporary control of severe bleeding in a variety of trauma and post surgical wounds. Bleed-X™ has been approved for over-the-counter use for cuts, lacerations and abrasions. Both are based on Medafor's MPH™ (Microporous Polysaccharide Hemospheres) technology - a biopolymeric, microporous powder which produces rapid hemostasis in areas of profuse bleeding.

"MPH offers medical professionals unprecedented safety, ease-of-use and cost-effectiveness in hemostasis and wound management," stated Medafor CEO Richard Zerban. "This FDA clearance enables us to put our advanced technology into the hands of medical professionals where they and their patients now can begin to benefit from its use. Based on extensive testing at the Mayo Clinic, the Minnesota Medical Research Foundation and elsewhere, we're confident that these products will have an immediate and significant impact on a variety of applications from the surgical suite to EMS First Response units to the neighborhood soccer match."

The TraumaDex and Bleed-X applications of the MPH technology initially will be directed to the emergency medical services, dermatology and over-the-counter industrial first aid markets. Subsequent launches will address military field applications and post-surgical wound management.

MPH is a novel hemostatic technology using microporous polymer particles which, when applied to a bleeding wound site, initiate coagulation within seconds. The particles act as molecular sieves to absorb fluids in the blood, attracting and concentrating proteins and platelets and accelerating the natural clotting cascade.

Medafor, Inc., is a privately held Minnesota corporation, founded in 1999 to develop and market applications of its patented, groundbreaking hemostatic technology.

This release may contain forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate, or unforeseen risks or circumstances materialize, actual results could vary materially from expectations and projections stated herein. The company assumes no obligation to update any forward-looking statements as a result of new information or future developments. BACK.